# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innov...
89bio, Inc (NASDAQ: ETNB) was plunging almost 10% lower on Friday in sympathy with the general market, which saw the S&P 50...
Piper Sandler analyst Yasmeen Rahimi maintains 89bio (NASDAQ:ETNB) with a Overweight and lowers the price target from $54 to...
89bio (NASDAQ:ETNB) has observed the following analyst ratings within the last quarter:
Barclays cut the price target on Avis Budget Group, Inc. (NASDAQ: CAR) from $245 to $223. Avis Budget shares rose 2.3% to $...
Oppenheimer analyst Jay Olson maintains 89bio (NASDAQ:ETNB) with a Outperform and lowers the price target from $49 to $40.
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wedne...
Â
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 102.6% to $0.1580 after declining 9% on Wednesday. Allena Pharmac...